ETIOTROPIC THERAPY FOR DIFFERENT FORMS OF HEPATITIS B
Abstract
Background. Currently, etiotropic therapy of hepatitis B in most cases is carried out using nucleot(s)ide analogues. The ultimate goal of the therapy depends on the period of its administration – in acute or chronic hepatitis. The influence of the molecular genetic profile of the hepatitis B virus on the effectiveness of therapy in both acute and chronic forms of the disease has not yet been established, which requires further research. Objective. To assess the possibilities of modern etiotropic therapy in acute and chronic forms of hepatitis B. Material and methods. The article analyzes the indicators of clinical, laboratory and instrumental data of patients who received etiotropic therapy with nucleot(s)ide analogues. Results. Etiotropic therapy resulted in a viral load decrease to an undetectable level in all patients regardless of the course of hepatitis B and infection with either a "mutant" or "wild" virus strain. In acute hepatitis B, HBV DNA was not detected in 100% of cases after 24 weeks of therapy, in HBsAg seroconversion - after 36 weeks; in chronic hepatitis B - after 36 weeks without HBsAg seroconversion. Six months after the completion of the treatment, the patients with chronic hepatitis B developed relapse in 89.7% of cases, but the viral load was less than 2000 IU / ml, and the severity of liver fibrosis was insignificant. In the rest of the cases, resumption of therapy was required. Conclusions. It was found that mutations of the hepatitis B virus do not affect the effectiveness of etiotropic therapy. The rate of viral load decrease correlates with the form of hepatitis B and is significantly higher in acute disease.References
World Health Organization. Globalnaja strategija sektora zdravoohranenija po virusnomu gepatitu 2016-2021 na puti k likvidacii virusnogo gepatita [Internet]. Available from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/ru/. (Russian).
Mikhaylov MI, Yushchuk ND, Malinnikova EYu, Kyuregyan KK, Isaeva OV, Znoyko OO, Klimova EA. Proekt programmy po kontrolju i likvidacii virusnyh gepatitov kak problemy obshhestvennogo zdorovja v Rossijskoj Federacii [The design of the program for control and elimination of viral hepatitis as public health problem in the Russian Federation]. Infekcionnye bolezni: novosti, mnenija, obuchenie [Infectious diseases: news, views, education]. 2018;7(2):52-58. https://doi.org/10.24411/2305-3496-2018-12005. (Russian).
Polyanina AV, Bystrova TN. Molekuljarno- jepidemiologicheskaja harakteristika virusa gepatita B v uslovijah massovoj vakcinoprofilaktiki [Molecular and epidemiological characteristics of hepatitis B virus in conditions of mass vaccine prophylaxis]. Zhurnal MediAl [Journal MediAl]. 2019;24(2):10-39. https://doi.org/10.21145/2225-0026-2019-2-10-39. (Russian).
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33(2):e00046-19. https://doi.org/10.1128/CMR.00046-19.
Zampino R, Sagnelli C, Boemio A, Sagnelli E, Coppola N. Treatment of chronic HBV infection in developing countries. Ann Hepatol. 2016;15(6):816-823. https://doi.org/10.5604/16652681.1222096.
SorianoV,BarreiroP,CachayE,KottililS,Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020;7:2049936120965027. https://doi.org/10.1177/2049936120965027.
Mehta P, Reddivari AKR. Hepatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554549/.
Zaitsev IA, Novak IM, Zaitseva OYe, Kiriienko VT. Genotipy HBV i protivovirusnaja terapija gepatita B [HBV genotypes and antiviral therapy of hepatitis B]. Aktualnaja infektologija [Аctual infectology]. 2019;7(4):189-195. https://doi.org/10.22141/2312-413x.7.4.2019.178879. (Russian).
Alexopoulou A, Vasilieva L, Karayiannis P. New Approaches to the Treatment of Chronic Hepatitis B. J Clin Med. 2020;9(10):3187. https://doi.org/10.3390/jcm9103187.
Efremova OS, Yurin OG. Sravnitelnaja harakteristika osnovnyh mezhdunarodnyh i nacionalnyh rekomendacij po lecheniju hronicheskogo gepatita B [Comparative characteristics of major international and national guidelines for the treatment of chronic hepatitis B]. Epidemiologija i infekcionnye bolezni. Aktualnye voprosy [Epidemiology and infectious diseases. Current items]. 2016;(2):48-57. (Russian).
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370- 398. https://doi.org/10.1016/j.jhep.2017.03.021.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. https://doi.org/10.1002/hep.29800.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98. https://doi.org/10.1007/s12072-015-9675-4.
Esaulenko EV, Sukhoruk AA. Transplantacija pecheni v detskom vozraste i u vzroslyh [Liver transplantation in children and adults]. Pediatr [Pediatrician]. 2015;6(3):98-103. https://doi.org/10.17816/PED6398-103. (Russian).
Abd El Aziz MA, Sacco R, Facciorusso A. Nucleos(t) ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antivir Chem Chemother. 2020;28:2040206620921331. https://doi.org/10.1177/2040206620921331.
Priima EN, Novak KE, Esaulenko EV, Ivanova NV, Alekseeva MV. Klinicheskaja znachimost molekuljarno- geneticheskogo issledovanija genoma virusa pri ostrom virusnom gepatite B [The clinical significance of molecular genetic research of the virus genome in acute viral hepatitis B]. Vestnik Novgorodskogo gosudarstvennogo universiteta [Vestnik NovSU]. 2019;113(1):60-65. https://doi.org/10.34680/2076-8052.2019.1(113).60-65. (Russian).
Ellaeva EA, Poretskova EA, Pisareva MA, Alikyan AU, Galbreikh RB, Grudinin MP, Yesaulenko EV. Genotipicheskaja harakteristika virusa gepatita B u hronicheski inficirovannyh bolnyh [Genotypic characteristics of viral hepatitis in chronically infected patients]. Dalnevostochnyj Zhurnal Infekcionnoj Patologii [The Far Eastern Journal of Infectious Pathology]. 2009;15(15):55-58. (Russian).
Priima EN, Alekseeva MV, Ivanova NV. Vlijanie mutacij v PRE-CORE oblasti genoma virusa gepatita B na effektivnost terapii ostrogo gepatita B. In: Gorodin VN, Zhukova LI, Lebedev PV, editors. Socialno-znachimye i osobo opasnye infekcionnye zabolevanija. Materialy V Vserossijskoj mezhdisciplinarnoj nauchno-prakticheskoj konferencii s mezhdunarodnym uchastiem; 2018 Oct 30 - Nov 2; Sochi. Krasnodar: OOO «Tipografija B+»; 2018. p. 195-197. (Russian).
Corrêa ASM, Lamarão LM, Vieira PCM, de Castro RBH, de Almeida NCC, de Castro JAA, de Lima MSM, Palmeira MK, Meireles ALLP, Burbano RR. Prevalence, incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil. PLoS One. 2018;13(12):e0208414. https://doi.org/10.1371/journal.pone.0208414.
Esaulenko EV, Nikitina OE, Poreckova EA, Pisareva MM. Virusnaja nagruzka pri hronicheskom gepatite B: korreljacii s laboratorno-morfologicheskimi pokazateljami. Zhurnal infektologii. 2012;4(2):67-72.
Bertoletti A, Le Bert N. Immunotherapy for Chronic Hepatitis B Virus Infection. Gut Liver. 2018;12(5):497-507. https://doi.org/10.5009/gnl17233.
Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. Curr Opin HIV AIDS. 2017;12(3):302-314. https://doi.org/10.1097/COH.0000000000000370.
Wooddell CI, Gehring AJ, Yuen MF, Given BD. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses. 2021;13(4):581. https://doi.org/10.3390/v13040581.
1.png)
